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Abstract
Exclude experimental models of malignant transfor-
mationemploychemical andphysical carcinogensorge-
netic manipulations to study tumor progression. In this
work, different melanoma cell lines were established
after submitting a nontumorigenic melanocyte lineage
(melan-a) to sequential cycles of forced anchorage
impediment. The great majority of these cells underwent
anoikis when maintained in suspension. After one de-
adhesion cycle, phenotypic alterations were noticeable
in the few surviving cells, which becamemore numerous
and showed progressive alterations after each adhe-
sion impediment step. No significant differences in cell
surface expression of integrins were detected, but a
clear electrophoretic migration shift, compatible with an
altered glycosylation pattern, was observed for B1 chain
in transformed cell lines. In parallel, a progressive en-
richment of tri- and tetra-antennary N-glycans was
apparent, suggesting increased N-acetylglucosaminyl-
transferase V activity. Alterations both in proteoglycan
glycosylation pattern and core protein expression were
detected during the transformation process. In conclu-
sion, this model corroborates the role of adhesion state
as a promoting agent in transformation process and
demonstrates that cell adhesion disturbances may act
as carcinogenic stimuli, at least for a nontumorigenic
immortalized melanocyte lineage. These findings have
intriguing implications for in vivo carcinogenesis, sug-
gesting that anchorage independencemay precede, and
contribute to, neoplastic conversion.
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Introduction
The incidence of melanoma in most developed countries
has increased more quickly than any other cancer type over
the past 50 years [1]. Melanoma arises from the malignant
transformation of pigment-producing cells (melanocytes), and
this process results from complex interactions between genetic
and environmental factors. Melanocytic nevi (moles), formed
by benign clusters of melanocytes, have drawn special atten-
tion as potential precursor lesions, and ‘‘atypical nevi’’ are
a marker for an increased risk of melanoma [2]. In vivo, 20%
to 30% of human malignant melanomas are associated with
benign or dysplastic nevi in histologic contiguity [3,4]. Clark
et al. [5] proposed a five-stage model of melanoma progres-
sion from preneoplastic lesions (benign and dysplastic nevi) to
thin radial growth superficial melanoma, followed by an inva-
sive lesion and culminating in metastatic disease.
In humans, one of the first tissue alterations involved in
melanoma progression is the presence of melanocytes in the
dermis, topographically distant to basal keratinocytes. Keratino-
cytes in the ‘‘epidermal melanin unit’’ play a fundamental role in
controlling the proliferation and expression of adhesion mole-
cules in melanocytes, loss of cell–cell contact, and disruption
of tissue architecture. Such activities have recently been impli-
cated in genotypic and phenotypic changes in melanocytes [6].
The extracellular matrix (ECM) surrounding the cells is an-
other important element controlling cell proliferation, adhesion,
and migration. Changes in the expression or function of ad-
hesion molecules, such as integrins, Mel-CAM/MUC18, CD44,
intercellular adhesion molecule-1, cadherins, and cell surface
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proteoglycans (PGs), have all been documented in the
progression of primary melanomas [7,8]. In particular, the
switch from a low-risk radial to a high-risk vertical growth
primary melanoma is characterized by significant changes in
the expression of molecules involved in cell–cell and cell–
ECM contact, as well as of proteases [9].
Cell–ECM interactions have also been shown to deter-
mine the molecular progression of poorly metastatic mela-
noma cells, changing them to exhibit a highly aggressive
phenotype [10]. The acquisition of resistance to cell death
induced by substrate adhesion blockade (anoikis resistance)
is a hallmark of neoplastic transformation and is also a criti-
cal step during metastatic progression [11].
Most findings relating adhesion molecules and the trans-
formation process were obtained from primary skin cultures
or human melanoma lesions in different stages of progres-
sion. Until now, all experimental models of melanocyte
transformation utilize chemical or environmental carcino-
gens and genetic manipulations to study the progression of
this deadly disease. In this work, we describe an in vitro
murinemodel that focuses on cellular adhesion blockade as a
transforming factor and characterize some alterations
in adhesion molecule expression, which accompanies mela-
nocyte transformation.
Materials and Methods
Cell Lines and Culture
The nontumorigenic murine melanocyte lineage, melan-a
[12], a kind gift of Dr. Michel Rabinovitch (Department of
Parasitology, UNIFESP, Sa˜o Paulo, Brazil), was cultured in
RPMI (pH 6.9; Gibco, Carlsbad, CA), supplemented with 5%
fetal calf serum (Gibco) and 200 nM 12-o-tetradecanoyl
phorbol-13-acetate (PMA; Tocris, Ellisville, MO) at 37jC in
a humidified atmosphere of 5% CO2 and 95% air. Melanoma
cell lines (4C3, 4C8, 4C11, Tm1, Tm5, and S11) derived from
melan-a cells after sequential cycles of substrate adhesion
impediment were cultured in the same conditions, without
PMA. Cell proliferation was determined using a standard
methyl thiazol tetrazolium (MTT) assay [13].
Anchorage-Independent Growth Assays
The nontumorigenic cell line melan-a (105 cells/ml) was
plated on 1% agarose and cultured for 96 hours in conditions
described above. Small spheroids were collected by de-
cantation and plated on standard culture plates, favoring cell
adhesion. Cells were allowed to proliferate to subconfluent
growth. The deadhesion (spheroid formation) cycle was re-
peated for four or five times; after the last deadhesion step,
spheroids were counted and plated by limiting dilution (0.5–
1 spheroid/well). Melan-a cells submitted to two and four
deadhesion cycles were named, respectively, 2C and 4C.
Tm1, Tm4, Tm5, S11, and 14 other melanoma cell lines were
obtained by cloning melan-a cells submitted to five dead-
hesion cycles. In a second melan-a deadhesion assay, 4C3,
4C8, 4C11, and five other melanoma cell lines were estab-
lished after four deadhesion steps.
Adhesion Assays
Briefly, 96-well microtiter plates were coated with 0.5 mg of
human plasma fibronectin (Sigma, St. Louis, MO) or human
placenta laminin (Calbiochem, San Diego, CA) in phosphate-
buffered saline (PBS), incubated at 37jC for 2 hours, and
blocked with 1% bovine serum albumin (BSA) for 1 hour after
washing. Cells (3  104) suspended in 100 ml of serum-free
RPMI were added to each coated well and incubated at
37jC for 30 minutes. Wells were washed three times with
cold PBS to remove unbounded cells. Viable adherent cells
were quantified using a standard MTT assay [13].
Immunofluorescence Microscopy
Different cell lines were cultured on glass coverslips until
subconfluence and fixed in 1% paraformaldehyde in PBS.
After washing with PBS, 50 mM glycine (pH 7.4) was added
for 1 hour, and coverslips were blocked with 1% BSA. Cells
were incubated for 1 hour with rabbit anti-fibronectin polyclonal
antibody (Calbiochem), washed with 1% BSA, and incu-
bated with an fluorescein isothiocyanate (FITC)–conjugated
anti-rabbit antibody (KPL, Gaithersburg, MD) for 45 minutes.
Slides were mounted and observed in a fluorescence micro-
scope (Nikon Inc., Melville, NY).
Analysis of Surface Molecule Expression by Flow Cytometry
Expressions of integrins (av,a5,a6, b1, and b3 subunits) and
leukoagglutinin from Phaseolus vulgaris (L-PHA)–positive
glycoconjugates were quantified by flow cytometry. The cells
were detached with trypsin, washed and suspended in PBS
(1  106 cells/100 ml), and incubated with primary antibodies
or FITC-conjugated L-PHA (Sigma; for L-PHA–positive gly-
coconjugates) on ice for 1 hour. All antibodies were diluted
in PBS containing 0.5% BSA. The cells were then washed
twice, suspended in 100 ml of appropriate FITC-conjugated
anti-IgG on ice for 45 minutes, washed twice, and suspended
in PBS. Negative controls were incubated only with sec-
ondary antibody. At least 10,000 cells were analyzed by Cell-
QUEST program using FACSCalibur (Becton Dickinson
Immunocytometry Systems, Franklin Lakes, NJ).
Western Blot Analysis and Lectin Blotting
Cells were washed twice with PBS and lysed in a buffer
containing 1%Triton, 150mMNaCl, 50mMTris HCl (pH 7.4),
5 mM EDTA, and protease and phosphatase inhibitors
(0.5 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin,
10 mg/ml aprotinin, and 1 mM sodium orthovanadate) on
ice for 15minutes. The lysateswere pelleted by centrifugation
for 15 minutes at 4jC, and protein concentration was deter-
mined using the Bradford reagent (Bio-Rad, Hercules, CA).
Equal amounts of protein (80 mg of total protein) from each
sample were resolved by reduced 7.5% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
gels and blotted onto polyvinylidine fluoride membranes
(Amersham, Piscatway, NJ). Membranes were blocked with
5% dried milk in PBS for 1 hour at room temperature be-
fore exposure to primary antibodies to b1 integrin (rabbit
polyclonal serum; a kind gift from Dr. K. Yamada, National
Institute for Dental Research, Bethesda, MD) for 2 hours at
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room temperature. Membranes were washed in 5% dried
milk containing PBS and incubated with horseradish peroxi-
dase (HPR)–conjugated anti-rabbit IgG (Sigma). After
extensive washing with PBS, proteins were visualized by
incubating the membrane with the substrate for peroxidase,
diaminobenzidine (DAB; Sigma). For lectin blotting, after in-
cubating the membrane with blocking reagent (Boehringer
Mannheim, Mannheim), 1 mg/ml biotinylated L-PHA (Sigma)
in blocking solution was added for 2 hours, followed by incu-
bation with streptavidin HPR (R&D Systems, Minneapolis,
MN) for another 1 hour at room temperature. The blots were
washed and developed with DAB.
Tumorigenicity Assays
Cells were harvested after trypsin treatment of subcon-
fluent monolayers, counted, and then suspended in PBS.
Melan-a cells (2  107 cells) and its derived clones (1 
106 cells) were injected subcutaneously in the flank of syn-
geneic 6- to 8-week-old C57Bl/6 female mice. Animals were
kept under 12-hour daylight cycles, without food restriction,
and checked daily for tumor development. Each experimental
group consisted of at least five animals. Subcutaneous
masses and axillary lymph nodes were excised and submit-
ted to histologic analysis after paraffin embedding and he-
matoxylin and eosin (H&E) staining.
PG and Glycosaminoglycan (GAG) Analysis
Cell cultures were radiolabeled with 150 mCi of carrier-free
35[S]sulfate (IPEN, Sa˜o Paulo, Brazil) for 18 hours, essen-
tially as previously described [14]. The medium was sepa-
rated, and the cell layer andECMwere removedwith 7Murea
in 12.5 mM Tris–HCl (pH 8.0). Each experiment was carried
out in triplicate. For PG analysis, protease inhibitors were
added to a final concentration of 100 mM a-aminocaproic
acid, 6.5 mM benzamidine HCl, 5.5 mM iodoacetamide, and
0.1 mM phenylmethylsulfonyl fluoride. Total protein con-
tent was determined using the Bradford reagent and BSA
as standard. For GAG analysis, 50 mM Tris–HCl buffer
(pH 8.0), containing 0.15 M NaCl and 2 mg/ml maxatase
(Biocon, Rio de Janeiro, Brazil), was added. The mixture
was incubated at 50jC overnight and then at 100jC for
10 minutes to inactivate the protease. PG and sulfated
glycosaminoglycan (SGAG)–free chains were analyzed by
agarose gel electrophoresis in 50 mM 1,3-diaminopropane
acetate buffer (pH 9.0), according to Nader et al. [15]. Elec-
trophoresis was run for about 1 hour at 100 V, and com-
pounds were precipitated in the gel with 0.1% CETAVLON
(N-cetyl-N,N,N-trimethylammonium bromide) for at least
2 hours. The gel was dried and stained with 0.1% toluidine
blue in 1% acetic acid and 50% ethanol. SGAG identifica-
tionwas based on themigration of the compounds, compared
to standards, after exposure to X-ray film and degradation
by specific enzymes [16]. Gel slices were cut and counted
in scintillation liquid for the quantification of [35S]sulfate-
radiolabeled SGAG. Relative contents of disaccharides in
chondroitin sulfate (CS) and dermatan sulfate (DS) were
determined after incubation of SGAG (25,000 cpm) with
chondroitinases AC (Tris–acetate 50 mM, pH 8.0) and ABC
(ethylene diamine acetate buffer, EDA 0.05 M, pH 8.0)
(Seikagaku, Tokyo, Japan). The relative amounts of disac-
charides in heparan sulfate (HS) were determined after di-
gestion of heparitinases I and II (0.05MEDA, pH 7.0) [17,18].
Incubation mixtures were applied to descending paper chro-
matography [isobutyric acid: 1.25 M NH4OH (5/3, vol/vol)].
Sulfated disaccharides were localized after exposure of the
chromatogram to an X-ray film, cut, and counted in scintil-
lation liquid.
Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total RNA were extracted from cultures with Trizol (Invi-
trogen, Carlsbad, CA), according to the manufacturer’s in-
structions. One microgram of RNA was reverse-transcribed
to cDNA with Superscript III (Invitrogen), according to the
manufacturer’s recommendations. PCR amplification was
performed using the following primers: decorin (forward: 5V-
gggtttggacaaagtgccctgg-3V; reverse: 5V-gcctggtgcatcaac-
cttgg-3V; 512 bp), syndecan-4 (forward: 5V-tgctgctcctcggaggc-
ttc-3V; reverse: 5V-ccttgggctctgaggggaca-3V; 282 bp), versican
(forward: 5V-caaacccatgcctcaacggagg-3V; reverse: 5V-ccttca-
gcagcatcccatgtgcgt-3V; 300 bp), perlecan (forward: 5V-gcccg-
tgcacgctgagattga-3V; reverse: 5V-ggggcagaccctggatctaag-3V;
812 bp), heparanase (forward: 5V-ctcgagatgctgctgcgctcgaag-
cctgcg-3V; reverse: 5V-ccatggtcaagtgcaagcagcaactttggc-3V;
1261 bp), and b-actin (forward: 5V-cttcgagcaggagatggcc-3V;
reverse: 5V-ggtgcacgatggaggggccg-3V; 439 bp). Except for
heparanase, the annealing temperature used in PCR am-
plification was 60jC, with different cycles. PCR reactions were
performed in 25-ml reaction mixtures containing 75 mM Tris–
HCl (pH 9.0), 2 mM MgCl2, 50 mM KCl, 20 mM (NH4)2SO4,
0.4 mM of each deoxynucleotide triphosphate, 0.4 mM of each
primer, 1 U of BioTools DNA Polymerase—Recombinant
from Thermus thermophilus (BioTools, Madrid, Spain), and
1 ml of cDNA in different dilutions. After the initial denaturing
step for 5 minutes at 94jC, thermal cycling consisting of
35 cycles of 30 seconds, denaturing at 94jC, 30 seconds of
annealing at 60jC, and 1 minute of extension at 72jC was
carried out, followed by a final extension of 10 minutes at
72jC. For heparanase PCR, the reaction was performed
using Master Mix Kit (Promega Biosciences Inc., Madison
WI), 0.4 mM of each primer, 2 ml of cDNA, and 200 mM be-
taine. After a denaturing step at 94jC for 5 minutes, the fol-
lowing cycles were carried out: 5 cycles of 1 minute at 94jC,
1minute at 60jC, and 2minutes at 72jC; 20 cycles of 1minute
at 94jC, 1minute at 55jC, and 2minutes at 72jC; 10 cycles of
1 minute at 94jC, 1 minute at 50jC, and 2 minutes at 72jC;
and a final extension step of 7minutes at 72jC. PCR fragment
amplification was confirmed by agarose gel staining with
ethidium bromide.
Data Analysis
All experiments were repeated for at least two to three
times with similar results. One-way analysis of variance
(ANOVA) tests were used for most experiments, except where
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otherwise indicated. Statistical analysis was performed using
GraphPad Prism 3.03 software (GraphPad, San Diego, CA).
Results
A New Model for Studying Melanocyte Transformation
A nontumorigenic murine melanocyte lineage, melan-a
[12], was submitted to stressful conditions by blocking adhe-
sion to substrate, as described above and as depicted in
Figure 1. As expected for a nontumorigenic immortalized cell
line, the great majority of these cells underwent apoptosis
induced by adhesion blockade (anoikis). After cultivating
melan-a cells in agarose-coated plates for 96 hours, only
103 small spheroids per 106 plated cells were observed. Each
spheroid is probably derived from a single cell, thus suggest-
ing that only 0.1% of the initial cell number was able to resist
anoikis (Table 1).
Anoikis-resistant melan-a cells were cultured in adherent
conditions and submitted to new deadhesion cycles. Sur-
viving melan-a cells submitted to two, three, and four dead-
hesion cycleswere kept in adherent conditions anddesignated
2C, 3C, and 4C, respectively. Distinct lineages (4C3, 4C8,
4C11, S11, Tm1, Tm4, Tm5, and others) were obtained by
limiting dilution after a new deadhesion cycle of 4C cells
(0.5 spheroid/well) (Figure 1).
Altered morphology was observed in all melan-a–derived
cell lines (including 1C to 4C cells), which demonstrated
stable phenotypic characteristics and melanin production
(data not shown). Although melan-a cells require PMA as a
growth factor, all these lineages showed PMA-independent
growth, as described for human melanoma cell lines [19].
Furthermore, cell lines obtained after submitting melan-a cells
to adhesion impediment cycles showed increased spheroid
formation and shorter doubling times compared to the original
melan-a cells (Table 1). Immunofluorescence analysis using
a specific antibody showed that melan-a–derived sublines
Tm1 and Tm5 did not assemble fibronectin on the ECM, un-
like melan-a cells (Figure 2A). Curiously, tested cell lines ob-
tained after four or five deadhesion steps and after limiting
dilution (4C11, Tm1 and Tm5) showed higher adhesiveness
both to fibronectin (Figure 2B) and laminin (Figure 2C).
Considering several phenotypic characteristics asso-
ciated with neoplastic transformation that were observed in
melan-a–derived cell lines, in vivo tumorigenic capacity was
tested. Surprisingly, all lineages obtained after four dead-
hesion cycles were able to grow as tumors when injected
subcutaneously in syngeneic mice (Figure 2D), with different
latency times for tumor appearance (Table 1). In the first
melan-a detachment assay, we obtained 16 different cell
lines; 12 were injected in the subcutaneous tissue and
every one of them resulted in palpable tumors (from 5 to
20 mm in diameter) in all injected animals (groups of three to
five animals). Subcutaneous tumors derived from seven
cell lines (Tm1, Tm4, Tm5, S10, S11, a1, and a3) were sub-
mitted to histologic analysis, and all showed cytologic and
histologic characteristics of malignant cells. All cell lines, ex-
cept Tm1 and a1, showed a melanotic appearance at mi-
croscopy. In the second assay, eight cell lines were obtained.
Four of them (4C1, 4C3, 4C8, and 4C11) were injected into
syngeneic mice, and all resulted in subcutaneous tumors
when injected subcutaneouly.
When 106 cells were transplanted subcutaneouly into
animals, the amelanotic Tm1 and melanotic Tm5 cell lines
showed very short latency times for tumor appearance (up
to 10 days) compared to 4C3, 4C8, and 4C11 (at least
30 days). Spontaneous lymph node metastases were iden-
tified in animals injected subcutaneouly with 106 Tm1, Tm4,
Table 1. Some Phenotypic Alterations of Melan-A–Derived Lineages.
Cell Lines Spheroid
Formation (%)*
Melanin
Production
Latency
In Vivoy (days)
Doubling Time
In Vitro (hours)
Melan-a 0.1 + Nontumorigenic 22
2C ND + Nontumorigenic 22
4C ND + Nontumorigenic 20
4C3 ND  >33 ND
4C11 ND  >33 ND
S11 10 + <14 ND
Tm1 25  <10 18
Tm5 32 + <9 14
ND, not done.
*Number of spheroids formed after plating 106 cells in suspension.
yTumorigenicity of cells injected subcutaneously in the flanks of C57Bl/6 mice
(1 million cells per flank).
Figure 1. Experimental model of melanocyte transformation induced by adhesion impediment. Schematic representation of the experimental protocol that resulted
in melan-a transformation. After detachment from the substrate, surviving cells showed altered morphology and PMA-independent growth, even after one
deadhesion cycle (1C).
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and Tm5 melanoma cells (Figure 2E), but not with 4C3, 4C8,
or 4C11. Tm1, Tm4, and Tm5 showed in vivo characteristics
of an aggressive phenotype, whereas 4C3, 4C8, and 4C11
were considered indolent melanoma lineages.
Conversely, direct cloning of melan-a cells (not submitted
to the deadhesion protocol) did not render tumorigenic line-
ages (data not shown). Melan-a cells have never been
shown to be tumorigenic, even when a great number of cells
(2  107 cells/animal) were transplanted subcutaneouly into
mice and observed for at least 80 days.
Melanoma Cells Derived from Melan-A Showed Significant
Alterations in Glycoconjugates
Because malignant phenotype was acquired after repeti-
tive cycles of adhesion blockade, adhesion molecule expres-
sion was investigated. Integrins are an important family of
adhesion molecules involved both in cell–cell and cell–ECM
interactions, and alterations in their expression and/or pro-
cessing are frequent in several types of malignancies [20].
Surface expression of b1, b3, a5, a6, and av integrin chains
was determined by flow cytometry using specific antibodies,
Figure 2. Morphologic and functional characteristics of melan-a–derived cell lines. (A) Phase-contrast microscopy (upper panels) and indirect immuno-
fluorescence depicting fibronectin deposition on ECM by melan-a, Tm1, and Tm5 cells, using a specific polyclonal antibody against fibronectin (lower panels).
Adherent cell number, as measured by an MTT protocol, after plating cells for 30 minutes in fibronectin-coated (B) or laminin-coated (C) wells. Paired t test was
used for statistical comparisons between melan-a cells and derived lineages (*P < .05, **P V .01). Histologic analysis of tumor masses (D) and axillary lymph nodes
(E) obtained from syngeneic mice injected with 106 cells, 14 days after injection. The large arrow indicates axillary lymph node, and the small arrow shows
infiltrating melanoma cells. H&E staining, 40.
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and no substantial differences were found in their surface
expression levels (data not shown). Although we could not
detect differences on b1 integrin surface expression,Western
blot analysis revealed that melan-a–derived melanomas
(Tm1 and Tm5) have a b1-chain with a different migration
pattern on SDS-PAGE when compared to melan-a cells
(Figure 3D), suggesting a posttranslational processing of b1
integrins. The same altered electrophoresis mobility was
observed for the b1 integrin chain of a well-known murine
melanoma cell line B16F10.
As previously shown by our group and others [21], a
similar shift of b1 integrin chain migration pattern is observed
in several tumor types and is commonly related to aberrant
glycosylation resulting from N-acetylglucosaminyltrans-
ferase V (GnT-V) enzymatic activity. Tri-antennary or tetra-
antennary oligosaccharides formed by this enzyme activity
are recognized by L-PHA, and, as seen in Figure 3, A and B,
melan-a–derived melanomas show a higher expression of
L-PHA–positive surface glycoconjugates compared to their
parental cell line. Interestingly, cell lineages obtained after
submitting melan-a to two or four deadhesion cycles (2C and
4C cell lines) already demonstrate a slightly higher L-PHA–
binding glycoconjugate expression compared to melan-a.
The total glycoprotein profile, shown by lectin blotting on
Figure 3C, detailed qualitative and quantitative alterations
observed after melan-a transformation.
Another important class of glycoconjugates comprises
ECM and surface PGs, which have complex structures,
with a protein core bearing at least one GAG chain. GAGs
are involved in cell growth, cell migration, and cell–cell and
cell–matrix interactions—phenomena that are essential for
tumor development. Initial analysis revealed important
modifications in electrophoretic PG profiles, both from cell
surface and culture supernatant extracts (data not shown).
These results led us to investigate the GAG composition of
these glycoconjugates.
Melanoma Cells Present an Altered GAG Profile
Compared to That of Melan-A Melanocytes
We analyzed GAG chains from cells and culture super-
natants from melan-a, Tm1, Tm5, and S11 cells (Figure 4A).
Melan-a has a tendency to accumulate PGs bearing HS on
Figure 3. Melan-a transformation is accompanied by an increase in tri-antennary and tetra-antennary oligosaccharides and by modification in 1 integrin chain.
(A) Cell surface tri-antennary and tetra-antennary oligosaccharide expression on melan-a (ma), 2C, 4C, 4C3, 4C11, Tm1, and Tm5 cell surfaces analyzed by flow
cytometry using biotin –L-PHA lectin and FITC–streptavidin. (B) Proportion of L-PHA–positive cells (same experiment as in A) (C). Glycoproteins from cell
extracts containing tri-antennary and tetra-antennary N-glycans, as shown by lectin blotting using L-PHA lectin. Analysis by flow cytometry of tri-antennary and
tetra-antennary oligosaccharide expression, as recognized by L-PHA lectin (D). 1 integrin expression on melan-a (ma), Tm5, and B16F10 cells visualized by
Western blot analysis, using a specific polyclonal antibody.
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the cell surface and/or ECM, whereas tumorigenic mela-
noma cell lines tend to express both HS and CS/DS PGs.
There is a clear difference in the electrophoretic migration
of CS synthesized by melan-a and its derived melanoma
cell lines. A band shift toward standard DS suggested an
increase in the amounts of iduronic acid–containing disac-
charides in the galactosaminoglycans of tumorigenic sub-
lines. The amount of [35S]GAG in relation to total protein
content was determined for HS and CS/DS, showing a sig-
nificant decrease of HS chains in cell extracts (Figure 4B) and
supernatants (Figure 4C) from tumorigenic cell lines, com-
pared to those from melan-a cells. Such decrease in the
incorporation of sulfate into HS could reflect a decrease
in synthesis (sulfation) and/or an increase of chain degrada-
tion. In our model, this HS reduction can be explained by a
progressive increase in heparanase expression along the
melan-a transformation process, as depicted in Figure 4D.
Heparanase is involved in the degradation of both cell sur-
face andECMHSchains [22], and elevated expression of this
enzyme has been associated with tumor development and
metastasis [23–25] In addition, HS disaccharide composition
was very similar in melan-a and in its derived sublines, except
for the Tm1 melanoma cell line. HS from Tm1 showed a de-
crease in the disaccharide bearing 2-O-sulfate in the uronic
acid residue in relation to parental melanocytes (Table 2).
The sulfated disaccharide composition for both secreted
and cellular CS/DS from each cell type was determined after
digestion with chondroitinases AC and ABC (Table 3). There
is a clear difference in the ratio of glucuronic acid– and
iduronic acid–containing disaccharides obtained by the
degradation of galactosaminoglycans when comparing
parental melanocyte lineage and its derived tumorigenic
melanoma cell line. Melan-a cells had mainly galactosami-
noglycan chains enriched in glucuronic acid–containing
disaccharides, whereas in tumorigenic counterparts, an im-
portant increase in the relative amounts of iduronic acid–
containing disaccharides was observed. Furthermore, the CS/
DS chains of the tumorigenic cells also showed 6-sulfated
disaccharides, which were not detected in the parental
cell line.
Figure 4.Melanoma cell lines show a band shift of CS toward DS and decreased levels of HS. (A) GAGs from cellular extracts and culture supernatants of melan-a
(ma) and derived melanoma cell lines (Tm1, Tm5, S11). (B and C) [35S]sulfate incorporation in CS/DS and HS chains. Total amount of [35S] incorporated in each
SGAG was determined by cutting radioactive bands from gel slides, counting in scintillation liquid, and normalizing for the protein content (cpm/g protein) of cell
extracts (B) and culture supernatants (C). (D) Heparanase mRNA expression (Hep) in melan-a (ma), melan-a maintained in suspension for 24 hours (D24 h), and
Tm1 and Tm5 melanoma cells. CS, chondroitin sulfate; DS, dermatan sulfate; HS, heparan sulfate.
Table 2. Relative Proportion of Heparan [35S]Sulfate Disaccharides Yielded
by Degradation with Heparitinases I and II.
HS Supernatants Cell Extracts
ma Tm1 Tm5 S11 ma Tm1 Tm5 S11
DUA-GlcNAc,6S 11 10 10 11 9 9 8 10
DUA-GlcNS 41 37 34 36 33 33 25 31
DUA-GlcNS,6S 29 43 41 35 36 44 44 35
DUA,2S-GlcNS,6S 19 11 15 18 22 14 23 24
The radioactivity of the disaccharides was measured after the separation (by
paper chromatography) of compounds incubated with both heparitinases I
and II. The types of uronic acid were not taken into account.
ma,melan-a; Tm1, Tm5, andS11, tumorigenicmelanomacell lines;DUA-GlcNS,
O-(4-deoxy-hex-4-enopyranosyluronic acid)-(1 –4)-2-sulfamino-D-glucose;
DUA-GlcNAc,6S, O-(4-deoxy-hex-4-enopyranosyluronic acid)-(1–4)-2-acetamido-
D-glucose 6-sulfate; DUA-GlcNS,6S, O-(4-deoxy-hex-4 enopyranosyluronic
acid)-(1–4)-2-sulfamino-D-glucose 6-sulfate; DUA,2S-GlcNS,6S,O-(4-deoxy-
hex-4-enopyranosyluronic acid 2-sulfate)-(1 –4)-2-sulfamino-D-glucose.
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Melanocyte Transformation Is Accompanied by Alterations
in Decorin, Versican, and Perlecan Expressions
To better characterize PG expression alterations that
occur during melanocyte transformation induced by cycles
of substrate adhesion blockade, we analyzed protein core
expression by semiquantitative RT-PCR (Figure 5). We also
analyzedmelan-a cells submitted to two and four deadhesion
cycles (2C and 4C cell lines) and two other melanoma cell
lines (4C3 and 4C8) for protein core transcripts. Perlecan,
versican, and decorin (but not syndecan- 4) protein core
expressions were altered in melanoma cell lines, compared
to those in melan-a and 2C cells. Interestingly, nontumori-
genic 2C and 4C cell lines, submitted to two and four dead-
hesion cycles, already showed some of these modifications,
suggesting that these PGs are associated with melanocyte
transformation in our model.
Discussion
Acquisition of anchorage-independent growth is a hallmark
of neoplastic transformation, but this property is not consid-
ered to be carcinogenic per se. In this work, we show that
repetitive adhesion blockade events are sufficient to induce
malignant transformation in nontumorigenic immortalized
melanocytes (melan-a). Although we cannot exclude clonal
selection as the principal mechanism responsible for tumori-
genic conversion, several results indicate that adhesion
impediment may trigger the carcinogenic process. All tumori-
genic cell lines derived from melan-a have faster doubling
times than their parental lineage (Table 1), but even after
80 in vitro passages, melan-a cells were never tumorigenic
in vivo (data not shown). No negative influence of melan-a
over its derived subline proliferation rate could be demon-
strated either in vitro (not shown) or in vivo [26]. In addition,
cell clones obtained after limiting the dilution of melan-a cells
Table 3. Relative Proportion of Chondroitin [35S]Sulfate/Dermatan [35S]Sul-
fate Disaccharides Yielded by Degradation with Chondroitinases AC and ABC.
CS/DS Supernatants Cell Extracts
ma Tm1 Tm5 S11 ma Tm1 Tm5 S11
DIdoA-GalNAc,4S 0 23 30 20 22 9 26 30
DGlcA-GalNAc,4S 100 57 46 57 78 76 50 57
DGlcA-GalNAc,6S 0 20 24 23 0 15 24 13
The radioactivity of the disaccharides was measured after separation by
paper chromatography. Chondroitinase AC exclusively yields glucuronic
acid–containing disaccharides, whereas chondroitinase ABC yields both
glucuronic acid– and iduronic acid–containing disaccharides. The relative
amount of DIdoA-4S was obtained by the difference between degradation
product yields after the action of both chondroitinases.
ma, melan-a; Tm1, Tm5, and S11, tumorigenic melanoma cell lines; DIdoA-
GalNAc,4S,O-(4-deoxy-hex-4-enopyranosyluronic acid)-(1–3)-2-acetamido-D-
galactose 4-sulfate; DGlcA-GalNAc,4S, O-(4-deoxy-hex-4-enopyranosyluronic
acid)-(1 –3)-2-acetamido-D-galactose 4-sulfate; DGlcA-GalNAc,6S, O-(4-
deoxy-hex-4-enopyranosyluronic acid)-(1–3)-2-acetamido-D-galactose6-sulfate.
Figure 5. The expression of perlecan, versican, and decorin, but not syndecan-4, becomes altered during melan-a transformation. cDNA obtained from RT was
diluted and amplified by semiquantitative PCR for syndecan-4 (A), perlecan (B), versican (C), and decorin (D), with resulting products visualized on agarose gel.
Ethidium bromide staining intensity was analyzed for each gene and for an internal control (-actin). Numbers on the y axis represent the mean ratio between
protein core/-actin expression for each cell type, determined for four different cDNA dilutions. Amplified products from one initial cDNA dilution are depicted below
each panel for syndecan-4 (1:16), perlecan (1:16), versican (1:8), decorin (1:2), and -actin (same dilution as that of the respective protein core). ma, melan-a; D,
melan-a submitted to adhesion blockade for 24 hours. ANOVA tests were used for statistical analysis.
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were not tumorigenic in vivo, suggesting that transformed
cells are not initially present in the parental cell line (not
shown) and that repeated adhesion blockade is important to
induce malignant phenotype. Epigenetic modifications are
the most probable candidates to explain the myriad of
morphologic and molecular alterations observed after re-
peated deadhesion cycles, and preliminary results from
ongoing experiments in our laboratory indicate that such is
the case, indeed.
Stressful conditions resulting from cell–cell and cell–
substrate adhesion modifications have previously been
associated with malignant transformation. Rubin [27] has
consistently shown that high-density cultures yield tumori-
genic clones, which he attributes to clonal selection, without
excluding a direct effect of adhesion alterations in the carci-
nogenic process. Another group has shown that the forced
anchorage-independent growth of a nontumorigenic, immor-
talized epithelial cell line resulted in the acquisition of an
anoikis-resistant phenotype and in tumorigenesis [28]. As
demonstrated by Zhu et al. [29], selected anoikis-resistant
melanoma cells showed increased metastatic potential and
multiple alterations in their phenotypic properties. Diaz-
Montero and McIntyre [30] obtained anoikis resistance osteo-
sarcoma sublines through modifications of culture conditions,
attributing this phenotype to epigenetic events. Ongoing re-
search in our laboratory has shown that adhesion alterations
can also induce malignant transformation in the fibroblast
cell line NIH 3T3, implying adhesion loss as a crucial factor
for carcinogenesis in different cell types.
Interestingly, the proportion of spheroid formation for each
cell line (melan-a and derived lineages; Table 1) resembles
the percentage of soft agar cell growth from different phases
of melanocyte transformation [31], where melan-a corre-
sponds to dysplastic lesions and Tm melanoma cells corre-
spond to invasive melanoma. These results reinforce the
idea that the cell lines utilized in this work truly represent a
continuum along the transformation process.
Integrins, which are the most important class of adhesion
molecules related to ECM interactions, have been shown in
most cellular types to impart survival signals on adhesion to
substrate and surface clustering [32,33]. However, Lewis
et al. [34] showed that loss of integrin-mediated cell adhesion
may abrogate cell death in cells submitted to DNA damage,
through p19Arf and p53 signaling. In melan-a–derived cell
lines, no modification of b1, b3, a5, a6, and av integrin ex-
pression was detected (not shown). Nevertheless, an elec-
trophoretic migration shift was observed for b1 integrin
chain (Figure 3D), which has been demonstrated by sev-
eral groups, including ours, to be related to an aberrant
N-glycosylation pattern [35,36]. This alteration, caused by
GnT-V overexpression, is associated with acquisition of
migratory phenotype and tumor progression [37]. The forced
expression of GnT-V results in decreased fibronectin attach-
ment of colon carcinoma cells [38] possibly caused by
aberrant b1 integrin chain glycosylation [35], but this same,
the glycosylation pattern was associated with increased
fibronectin adhesion (Figure 2B) in the melanoma cell lines
presented here.
Although GnT-V expression was not investigated, a
marked increase of its products (GlcNAcb1,6Mana1,6–
branched surface molecules) was demonstrated for all
melan-a–derived cell lines in a progressive manner during
the transformation process (Figure 3, A and B). A qualita-
tive alteration in the N-glycosylation protein profile was
demonstrated for melanoma cells derived from melan-a
(Figure 3C). The above studies and our findings suggest
that GnT-V activity is causally associated with malignant
transformation because melan-a cells submitted to sequen-
tial deadhesion cycles (but not yet tumorigenic) already
show augmented levels of tri-antennary and tetra-antennary
N-glycan products.
Even though it is quite clear that several tumors accumu-
late glycoproteins bearing b1–6–branched N-linked oligo-
saccharides recognized by L-PHA, the precise function of this
altered pattern of glycosylation in glycoprotein function
remains elusive. An interesting hypothesis considering
GnT-V as a transforming enzyme was proposed by Dennis
et al. [39], who had initially shown that its forced expres-
sion in a nontumorigenic cell line could convert those cells
capable of forming tumors in nude mice [40]. Based on more
recent studies, Morgan et al. [41] proposed that growth
factor and cytokine receptors, which are also modified by
GnT-V, exist as lattices on the cell surface. Maintenance of
these lattices would depend on extracellular glycan-binding
proteins, such as galectins. Complexes of glycoproteins and
lectins would render cells more sensitive to growth factors,
whose interaction with their cognate receptors usually lead
to receptor dimerization/oligomerization. If correct, the pre-
diction is that L-PHA binding correlates with autonomous
growth. Integrins [35,42,43] and cadherins [44,45] are also
substrates of GnT-V. Similarly to integrins, no differences
in cadherin expression were detected by serial analysis of
gene expression [46], RT-PCR, or Western blot analysis
(data not shown). The higher adhesiveness of tumorigenic
cell lines (4C11 and Tm5), both to fibronectin and laminin
(Figure 2, B and C), could be attributed to this aberrant
glycosylation pattern present in b1 integrin chains. However,
the true impact of this pattern of glycosylation in this model
warrants further investigation.
PGs, another class of surface molecules, are also in-
volved in neoplastic transformation in several cell types. HS
and CS have been particularly implicated in tumor formation,
including melanoma, because of their capacity to bind and
modulate a large number of molecules that are important for
tumor development, such as basic fibroblast growth factor
and vascular endothelial growth factor [47]. HS may either
promote or inhibit tumor progression, depending on heparan
fragments generated on digestion [48]. In our model, the ex-
pression of HS was significantly decreased after transfor-
mation, although no structural modifications were discernible
(Figure 4; Table 2). In parallel, an increased expression of
heparanase was demonstrated not only in melan-a–derived
melanoma cell lines, but also in melan-a maintained in sus-
pension for 24 hours, indicating that heparanase may con-
tribute to early changes involved in melan-a transformation.
Using a different approach for the detection of heparanase
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in different melanoma cell lines, an increase in enzymatic
activity was related to a higher metastatic phenotype [49].
However, CS/DS levels were similar in both nontumorigenic
and tumorigenic cell lines, but their disaccharide composition
was clearly different from the parental cell lineage (Figure 4;
Table 3). It is clear that transformation leads to an increase in
the relative amounts of a-L-iduronic acid, suggesting a pos-
sible upregulation of the b-D-glucuronic acid C-5-epimerase.
Furthermore, during transformation, the glucuronic acid–
containing disaccharides show the presence of N-acetylga-
lactosamine-6-O-sulfate, contrasting with the parental line
that bears only N-acetylgalactosamine-4-O-sulfate, indicat-
ing that malignant transformation leads to the expression
of N-acetylgalactosamine 6-O-sulfotransferase, as previ-
ously observed in brain tumors [50].
In addition, the protein core expression levels of some
PG subclasses were determined by semiquantitative RT-
PCR. As shown in Figure 5, perlecan levels increase during
transformation, decorin and versican levels decrease, and
syndecan-4 level does not change. Among extracellular
PGs, decorin has emerged as an inhibitor of tumor progres-
sion, whereas perlecan seems to be a promoter of this pro-
cess [51,52]. Perlecan apparently supports the growth
and invasion of tumor cells through its ability to store angio-
genic factors [53]. This last observation also corroborates
our hypothesis that melan-a–derived melanoma cell lines
were not selected by multiple cycles of adhesion blockade
because perlecan increased during the transformation pro-
cess even in the absence of a selective pressure related
to angiogenesis.
Our model of melanocyte carcinogenesis allows the iden-
tification of morphologic and molecular alterations that
precede full malignant transformation and reinforce micro-
environmental role as a transforming factor, particularly the
loss of cell–substrate adhesion.
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